PT3297625T - Composto para a profilaxia ou tratamento de nefropatia diabética ou doença renal diabética - Google Patents

Composto para a profilaxia ou tratamento de nefropatia diabética ou doença renal diabética

Info

Publication number
PT3297625T
PT3297625T PT167233469T PT16723346T PT3297625T PT 3297625 T PT3297625 T PT 3297625T PT 167233469 T PT167233469 T PT 167233469T PT 16723346 T PT16723346 T PT 16723346T PT 3297625 T PT3297625 T PT 3297625T
Authority
PT
Portugal
Prior art keywords
prophylaxis
compound
treatment
organ damage
organ
Prior art date
Application number
PT167233469T
Other languages
English (en)
Original Assignee
Sulfateq Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56014996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3297625(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sulfateq Bv filed Critical Sulfateq Bv
Publication of PT3297625T publication Critical patent/PT3297625T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/723,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT167233469T 2015-05-22 2016-05-12 Composto para a profilaxia ou tratamento de nefropatia diabética ou doença renal diabética PT3297625T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2014843 2015-05-22

Publications (1)

Publication Number Publication Date
PT3297625T true PT3297625T (pt) 2022-09-27

Family

ID=56014996

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167233469T PT3297625T (pt) 2015-05-22 2016-05-12 Composto para a profilaxia ou tratamento de nefropatia diabética ou doença renal diabética

Country Status (15)

Country Link
US (2) US10676452B2 (pt)
EP (1) EP3297625B1 (pt)
JP (2) JP6967456B2 (pt)
CN (1) CN107660148B (pt)
AU (1) AU2016268975B2 (pt)
BR (1) BR112017024854B1 (pt)
CA (1) CA2986300C (pt)
CL (1) CL2017002960A1 (pt)
DK (1) DK3297625T3 (pt)
ES (1) ES2927699T3 (pt)
HU (1) HUE060167T2 (pt)
MX (1) MX2017014912A (pt)
PL (1) PL3297625T3 (pt)
PT (1) PT3297625T (pt)
WO (1) WO2016188766A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
MX2017014912A (es) * 2015-05-22 2018-06-13 Sulfateq Bv Compuesto para la profilaxis o el tratamiento de daño al organo.
EP3672592A1 (en) 2017-08-25 2020-07-01 Sulfateq B.V. 6-chromanol derivatives for use as a medicament
US20210128523A1 (en) 2017-08-25 2021-05-06 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
MX2020005238A (es) 2017-11-22 2020-08-24 Khondrion Ip B V Compuestos novedosos como inhibidores mpges-1.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681890A (en) 1984-10-30 1987-07-21 Kuraray Co., Ltd. 3,4-dihydrobenzopyran compounds and pharmaceutical composition containing the same
EP0202580B1 (en) 1985-05-13 1990-03-28 Kuraray Co., Ltd. 3,4-dihydrobenzopyran derivatives
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
US5266709A (en) 1989-03-13 1993-11-30 Ono Pharmaceutical Co., Ltd. Benzopyran derivatives
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
FR2756284B1 (fr) 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6335445B1 (en) 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
AU2823797A (en) 1997-05-02 1997-11-19 Dr. Reddy's Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US7456205B2 (en) 2003-02-26 2008-11-25 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Benzopyran compounds, process for preparing the same and their use
AU2004260758B2 (en) * 2003-08-01 2007-06-07 Nippon Soda Co., Ltd. Phenylazole compounds, production process, and antioxidants
US7470798B2 (en) * 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
DK2872497T4 (da) 2012-07-12 2019-11-25 Khondrion Ip B V Chromanyl-derivater til behandling af mitokondriel sygdom
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
MX2017014912A (es) * 2015-05-22 2018-06-13 Sulfateq Bv Compuesto para la profilaxis o el tratamiento de daño al organo.

Also Published As

Publication number Publication date
AU2016268975B2 (en) 2021-08-12
BR112017024854B1 (pt) 2023-12-26
AU2016268975A1 (en) 2017-11-30
CL2017002960A1 (es) 2018-03-16
US20210024485A1 (en) 2021-01-28
HUE060167T2 (hu) 2023-02-28
JP2021120381A (ja) 2021-08-19
CA2986300A1 (en) 2016-12-01
CN107660148A (zh) 2018-02-02
EP3297625A1 (en) 2018-03-28
DK3297625T3 (da) 2022-10-17
WO2016188766A1 (en) 2016-12-01
BR112017024854A2 (pt) 2018-08-14
JP6967456B2 (ja) 2021-11-17
MX2017014912A (es) 2018-06-13
CN107660148B (zh) 2021-03-09
US20180170892A1 (en) 2018-06-21
ES2927699T3 (es) 2022-11-10
CA2986300C (en) 2024-02-20
EP3297625B1 (en) 2022-07-06
JP2018520106A (ja) 2018-07-26
PL3297625T3 (pl) 2022-11-14
US10676452B2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
HRP20181772T1 (hr) Spoj za obradu gnojiva koje sadrži ureu
HK1247202A1 (zh) 用於治療癌症的化合物
IL253945A0 (en) kdm1a inhibitors to treat the disease
GB201715639D0 (en) Compositions for wound treatment
SI3261726T1 (sl) Sestavek za zdravljenje aken
PT3297628T (pt) Azasetron para uso no tratamento de perda auditiva
ZA201702884B (en) Compositions and methods for the treatment and prophylaxis of surgical site infections
PL3122349T3 (pl) Kompozycje do leczenia samotrawienia
IL249640A0 (en) Preparations for the treatment of nosebleeds
PT3297625T (pt) Composto para a profilaxia ou tratamento de nefropatia diabética ou doença renal diabética
PL3302573T3 (pl) Kompozycja do leczenia uszkodzeń mózgu
HK1247558A1 (zh) 塞內可瑞偉洛克(cenicriviroc)用於治療纖維化
EP3362085C0 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH MUCIN
PT3340975T (pt) Formulação para o tratamento de acne
IL255167A0 (en) Compounds for the treatment of cancer
SG11201706369PA (en) Compositions and methods for the treatment of mucositis
IL272124A (en) Treatment of non-inflammatory lesions
HK1250343A1 (zh) 用於治療聽力損失的司瓊類鈣調神經磷酸酶抑制劑
GB201717977D0 (en) Treatment of anaemia
GB201701928D0 (en) Compounds for the treatment of hyperglycaemia
PT3524255T (pt) Composição para o tratamento do acne
PL3273997T3 (pl) Kompozycja do leczenia nieżytu nosa
GB201510658D0 (en) Compositions for wound treatment
GB201413683D0 (en) Compound for the inhibition of citrate transporter
GB201405350D0 (en) Tri-substituted glycerol compounds for the treatment of multiple sclerosis